Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples